Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine:
”New NEJM trial: Apixaban vs Rivaroxaban in acute VTE
Clinically relevant bleeding:
Apixaban 3.3%
Rivaroxaban 7.1%
RR 0.46
- Similar efficacy for recurrent VTE
- Significantly lower bleeding with apixaban
However, an important limitation: Cancer-associated thrombosis patients were excluded from the trial.
So there is no direct evidence in oncology patients. Still, in daily oncology practice — especially in patients with higher bleeding risk — this signal may be worth keeping in mind when choosing between DOACs.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 15:12Edward C.C. Wong: Navigating the Implications of the 2026 ASH Guidelines for Blood Donation
-
Oct 30, 2026, 14:53Pall T. Onundarson: Anticoagulation Guidelines Under the Influence of Pharmaceuticalisation
-
Oct 30, 2026, 14:27Isabella Presch: From Innovation to Accessibility in Cell and Gene Therapy
-
Oct 30, 2026, 14:00Abdul Mannan: A Negative PCR Does Not Exclude β-Thalassaemia
-
Oct 30, 2026, 13:53Matteo Foschi: Can Thrombolysis Safely Treat Stroke After Cardiac Procedures?
-
Oct 30, 2026, 13:42Wolfgang Miesbach: Gene Therapy-Associated Leukaemia With Clonal Persistence Over 16 Years
-
Oct 30, 2026, 12:47Louise St. Germain Bannon: Turning Thrombosis Awareness into Stroke Prevention
-
Oct 30, 2026, 12:36Aryabhatta Sadhu: Sickle Cell Crisis Recognising When Treatment Must Change
-
Oct 30, 2026, 12:22Fabrice Cognasse: The Future of Blood Banks From Transfusion Support to Precision Medicine